Optimal design of trials to demonstrate the utility ofgenomically-guided therapy: Putting Precision CancerMedicine to the test

Molecular Oncology

Volumn 9, Issue 5, 2015, Pages 940-950

  Dienstmann, Rodrigo ^a   Rodon, Jordi ^b   Tabernero, Josep ^b  

^a SAGE BIONETWORKS   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Clinical trial design; Precision Cancer Medicine; Targeted therapy

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; EVEROLIMUS; LAPATINIB; SORAFENIB; VEMURAFENIB;

BREAST CANCER; CANCER RESEARCH; CLINICAL MEDICINE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COLORECTAL CANCER; DATA BASE; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; LONGITUDINAL STUDY; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECISION CANCER MEDICINE; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; GENE THERAPY; GENOMICS; NEOPLASMS;

CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GENOMICS; HUMANS; NEOPLASMS;

EID: 84928585501     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.06.014     Document Type: Review

References (34)

1. Andre F., Bachelot T., Commo F., et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014, 15:267-274.
2. Bedard P.L., Hansen A.R., Ratain M.J., Siu L.L. Tumour heterogeneity in the clinic. Nature 2013, 501:355-364.
3. Chabner B.A. Early accelerated approval for highly targeted cancer drugs. N.Engl. J. Med. 2011, 364:1087-1089.
4. Claret L., Gupta M., Han K., et al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J.Clin. Oncol. 2013, 31:2110-2114.
5. Cortes J.E., Kim D.W., Pinilla-Ibarz J., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N.Engl. J. Med. 2013, 369:1783-1796.
6. Dienstmann R., Rodon J., Barretina J., et al. Genomic medicine frontier in human solid tumors: prospects and challenges. J.Clin. Oncol. 2013, 31:1874-1884.
7. Dienstmann R., Rodon J., Tabernero J. Biomarker-driven patient selection for early clinical trials. Curr. Opin. Oncol. 2013, 25:305-312.
8. FDA Draft Guidance for Industry. Pathologic Complete Response in Neoadjuvant Treatment of High-risk Early-stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval 2012, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf.
9. FDA Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development 2013, http://www.fda.gov/downloads/scienceresearch/specialtopics/personalizedmedicine/ucm372421.pdf.
10. Ferte C., Fernandez M., Hollebecque A., et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin. Cancer Res. 2014, 20:246-252.
11. Ferte C., Koscielny S., Albiges L., et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. Eur. Urol. 2013, 65:713-720.
12. Garcia V.M., Cassier P.A., de Bono J. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress. Cancer Discov. 2011, 1:207-212.
13. Gerlinger M., Horswell S., Larkin J., et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 2014, 46:225-233.
14. Hoelder S., Clarke P.A., Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol. Oncol. 2012, 6:155-176.
15. Kim E.S., Herbst R.S., Wistuba I.I., Lee J.J., et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011, 1:44-53.
16. Le Tourneau C., Kamal M., Tredan O., et al. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target Oncol. 2012, 7:253-265.
17. Levy A., Hollebecque A., Ferte C., et al. Tumor assessment criteria in phase I trials: beyond RECIST. J.Clin. Oncol. 2013, 31:395.
18. LoRusso P.M., Anderson A.B., Boerner S.A., et al. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?. Clin. Cancer Res. 2010, 16:5956-5962.
19. McClellan M., Benner J., Schilsky R., et al. An accelerated pathway for targeted cancer therapies. Nat. Rev. Drug Discov. 2011, 10:79-80.
20. Nishino M., Giobbie-Hurder A., Gargano M., et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 2013, 19:3936-3943.
21. Ocana A., Amir E., Vera-Badillo F., et al. Phase III trials of targeted anticancer therapies: redesigning the concept. Clin. Cancer Res. 2013, 19:4931-4940.
22. Pemovska T., Kontro M., Yadav B., et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013, 3:1416-1429.
23. Piessevaux H., Buyse M., Schlichting M., et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J.Clin. Oncol. 2013, 31:3764-3775.
24. Rodon J., Saura C., Dienstmann R., et al. Molecular prescreening to select patient population in early clinical trials. Nat. Rev. Clin. Oncol. 2012, 9:359-366.
25. Roychowdhury S., Iyer M.K., Robinson D.R., et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 2011, 3:111ra121.
26. Schilsky R.L. Implementing personalized cancer care. Nat. Rev. Clin. Oncol. 2014, 11:432-438.
27. Simon R., Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat. Rev. Drug Discov. 2013, 12:358-369.
28. Sleijfer S., Bogaerts J., Siu L.L. Designing transformative clinical trials in the cancer genome era. J.Clin. Oncol. 2013, 31:1834-1841.
29. Tajik P., Zwinderman A.H., Mol B.W., et al. Trial designs for personalizing cancer care: a systematic review and classification. Clin. Cancer Res. 2013, 19:4578-4588.
30. Tran B., Brown A.M., Bedard P.L., et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int. J. Cancer 2013, 132:1547-1555.
31. Vermeulen L., de Sousa e Melo F., Richel D.J., et al. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012, 13:e83-89.
32. Xiao G., Ma S., Minna J., et al. Adaptive prediction model in prospective molecular signature-based clinical studies. Clin. Cancer Res. 2014, 20:531-539.
33. Yap T.A., Gerlinger M., Futreal P.A., et al. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 2012, 4:127ps10.
34. Yap T.A., Sandhu S.K., Workman P., et al. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 2010, 10:514-523.